Full-Time

Associate – Manager

Commercial Distribution

Posted on 9/3/2025

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

No salary listed

Remote in Australia

Remote

Category
Operations & Logistics (3)
, ,
Required Skills
Inventory Management
Customer Service
Data Analysis
Excel/Numbers/Sheets
Requirements
  • 5+ years progressive experience in Supply Chain within the biotech/pharmaceutical industry.
  • A minimum of 3 years in a logistics operation or customer service role.
  • Understanding of global pharmaceutical regulatory requirements, GMP and GDP.
  • Experience working in a global, complex supply chain organization within the biopharma or pharmaceutical industry.
  • Strong ability to collaborate and build strategic relationships with internal (Quality, Commercial, Finance, etc.) as well as external (CMO, customs brokers etc.) stakeholders.
  • Strong understanding of export/import requirements and customs practices.
  • Strong experience with initiating and leading process improvements.
  • Fluent in English.
  • Proficiency in Excel.
Responsibilities
  • Manage daily operations including warehousing and transportation with 3PL, reverse logistics and local relabeling / redressing operations where required.
  • Manage the Order to cash process including sales order processing, master data maintenance and credit management to ensure on-time order entry to support customer invoicing and reconciliation.
  • Liaise with global logistics and trade compliance to track inbound deliveries, including providing support for customs clearance, to ensure on time delivery, goods receipts, and goods release for distribution.
  • Manage and assess logistics vendor’s performance and monitor reports on operational metrics (KPIs), including regulatory reporting requirements related to local warehousing, distribution and import activities.
  • Ensure the requirements and business processes associated with goods are efficient and compliant with local regulations.
  • Support serialization implementation.
  • Liaise with accounting and the LSP to retrieve proof of delivery documents for end of month accounting purposes.
  • Perform reconciliation at the end of each month of LSP inventory transactions and inventory holding and compare to internal inventory management system holdings and transactions and investigate and rectify discrepancies and share with regional planning and quality where required.
  • Liaise with accounting, LSP and quality to coordinate annual stock count, reporting and discrepancy process.
  • Support new distributor / LSP integrations as needed.
  • Manage the warehouse and distribution budget.
  • Liaise with local launch teams and regional planner to support product launch and variation management.
  • Liaise with global logistics and trade compliance to support in country customs and freight services, oversee product issue and product receipt, and liaise with accounting to meet required reporting standards.
  • Provide logistical support and stock management for co-payment programmes.
  • Establish change records and manage these to support new launches.
  • Maintain wholesaler relationships and establish working relations to inform forecasting and planning.
  • Monitor for relevant tenders, coordinate and submit relevant documentation to support product utilisation.
  • Maintain metrics and analyze data to implement process improvements.
  • Lead and assist in the creation and improvements of Standard Operating Procedures and Policies.
  • Coordinate with quality team on product complaints/deviations/CAPAs for incidents that occur during local warehousing/distribution/importation.
  • Collaborate with cross-functional colleagues (including Finance, Marketing, Business Insights etc) to deliver the ANZ business goals and priorities.
  • Be an active member of the regional supply chain working group, providing support to colleagues across the region as needed.
  • Evaluate long-term logistics models and vendors, providing recommendations in partnership with procurement as local business needs change and evolve.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE